News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Roche Says MabThera Gets Positive Phase III Data
October 26, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, Oct 26 (Reuters) - Lymph cancer treatment MabThera has been shown to work as a maintenance therapy in patients with relapsed indolent non-Hodgkin's lymphoma, according to initial details from a Phase III study released by Roche on Wednesday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Europe
Roche
MORE ON THIS TOPIC
Obesity
Eli Lilly Keeps Obesity Pipeline Fresh With $1.3B Superluminal Partnership
August 14, 2025
·
1 min read
·
Dan Samorodnitsky
Pipeline
Schrödinger Cans Early-Stage Blood Cancer Drug After Two Patient Deaths
August 14, 2025
·
2 min read
·
Tristan Manalac
Inflammatory bowel disease
CytomX Reports Treatment-Related Patient Death in Phase I Colorectal Cancer Study
August 14, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Vedanta Downsizes by 20% After Phase II Stumble in Ulcerative Colitis
August 14, 2025
·
2 min read
·
Tristan Manalac
